TY - JOUR
T1 - Low Risk of Intracranial and Systemic Hemorrhages in Patients on Dual Antiplatelet Treatment Beyond 1 Month Following Neuroendovascular Angioplasty and/or Stent Placement
AU - Hassan, Ameer E.
AU - Zacharatos, Haralabos
AU - Vazquez, Gabriela
AU - Rodriguez, Gustavo J.
AU - Suri, M. Fareed K.
AU - Tummala, Ramachandra P.
AU - Taylor, Robert A.
AU - Qureshi, Adnan I.
N1 - Copyright:
Copyright 2012 Elsevier B.V., All rights reserved.
PY - 2012/1
Y1 - 2012/1
N2 - Background: Aspirin and clopidogrel treatment beyond 1 month in patients undergoing angioplasty and/or stent placement within the extra- and/or intracranial arteries is not defined. OBJECTIVE: To determine the incidence of intracranial and systemic bleeding events, recurrent ischemic stroke, and death in patients treated with dual antiplatelets for greater than 1 month. Methods: We determined rates of hemorrhage, stroke, or death in consecutive patients with extra- or intracranial lesions, treated with dual antiplatelets after angioplasty and/or stent procedures. Results: Dual antiplatelet treatment was initiated in 110 patients following endovascular treatment with a median treatment time period of 3 months (364 person-months of exposure). There were two bleeding events (1 intracranial and 1 gastrointestinal), 1 ischemic stroke, and no deaths. The rate of intracranial and systemic bleeding events, recurrent ischemic stroke, death due to stroke, or premature discontinuation was 8.3 per 1,000 person-months (95%, CI [2.7-25.6]). There were no bleeding events after the first month of treatment. Conclusion: We did not find an increased risk of adverse events in patients treated with dual antiplatelet treatment beyond 1 month after endovascular procedure, supporting the safety of intermediate-term treatment as adjunct to intra- and extracranial angioplasty and/or stent placement.
AB - Background: Aspirin and clopidogrel treatment beyond 1 month in patients undergoing angioplasty and/or stent placement within the extra- and/or intracranial arteries is not defined. OBJECTIVE: To determine the incidence of intracranial and systemic bleeding events, recurrent ischemic stroke, and death in patients treated with dual antiplatelets for greater than 1 month. Methods: We determined rates of hemorrhage, stroke, or death in consecutive patients with extra- or intracranial lesions, treated with dual antiplatelets after angioplasty and/or stent procedures. Results: Dual antiplatelet treatment was initiated in 110 patients following endovascular treatment with a median treatment time period of 3 months (364 person-months of exposure). There were two bleeding events (1 intracranial and 1 gastrointestinal), 1 ischemic stroke, and no deaths. The rate of intracranial and systemic bleeding events, recurrent ischemic stroke, death due to stroke, or premature discontinuation was 8.3 per 1,000 person-months (95%, CI [2.7-25.6]). There were no bleeding events after the first month of treatment. Conclusion: We did not find an increased risk of adverse events in patients treated with dual antiplatelet treatment beyond 1 month after endovascular procedure, supporting the safety of intermediate-term treatment as adjunct to intra- and extracranial angioplasty and/or stent placement.
KW - Angioplasty
KW - Antiplatelet
KW - Antiplatelets
KW - Aspirin
KW - Clopidogrel
KW - Neuroendovascular procedures
KW - Stent
UR - http://www.scopus.com/inward/record.url?scp=84855921861&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84855921861&partnerID=8YFLogxK
U2 - 10.1111/j.1552-6569.2010.00520.x
DO - 10.1111/j.1552-6569.2010.00520.x
M3 - Article
C2 - 20977528
AN - SCOPUS:84855921861
SN - 1051-2284
VL - 22
SP - 67
EP - 73
JO - Journal of Neuroimaging
JF - Journal of Neuroimaging
IS - 1
ER -